Sterile Aqueous Injectables and Steam Sterilization Cycle Design in Equine Emergency Formulations

Nikethamide is incorporated into sterile aqueous injectable solutions at a concentration of 250 mg/mL, equivalent to 25.0% w/v, a level retained from established analeptic formulations and suitable for low-viscosity water-for-injection systems at 20–25 °C. The bulk formulation is prepared in a closed 316L stainless-steel mixing vessel with a bottom-mounted magnetic agitator operated at 120–180 rpm; the API is added to water for injection at 35±2 °C and mixed until visually clear, after which pH is adjusted to 5.5–6.5 with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide. Because the molecule contains a tertiary amide, pH below 5.0 accelerates amide hydrolysis and pH above 7.5 increases free-amine degradation product levels; pH adjustment is therefore verified against Ph. Eur. 2.2.3 potentiometric pH determination. The bulk solution is clarified through a 0.45 µm polypropylene prefilter and sterilized by membrane filtration through a 0.22 µm PVDF cartridge filter into Type I borosilicate glass vials conforming to ISO 8362-1, closed with bromobutyl rubber stoppers conforming to ISO 8362-5. Terminal steam sterilization is performed in an air-overpressure autoclave at 121±1 °C for 15 minutes, with a measured lethality accumulator F₀ ≥ 15 minutes; thermocouple mapping of production loads above 10,000 vials is used to identify cold spots, and load bracketing follows VICH GL3 stability principles. Batch release testing requires Ph. Eur. 5.1.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins below 0.25 EU/mg, and sub-visible particulate counts meeting Ph. Eur. 2.9.19 test A and B for parenteral preparations. On production-scale lines, excessive hold time between buffer preparation and sterile filtration has been observed to lower recoverable API assay due to surface adsorption onto filter media; the operational boundary is therefore a maximum hold time of 4 hours at 20–25 °C. Terminal finished product types are 10 mL single-dose ampoules and 50 mL multidose vials intended for intravenous or intramuscular administration in equine respiratory depression associated with post-anesthetic recovery, barbiturate toxicity, or neonatal asphyxia.

In neonatal ruminant intensive care units, oral dosing with nikethamide is compounded as a 2.5% w/v non-sterile aqueous solution intended for drench or bottle administration where requiring pharyngeal stimulation. The vehicle is prepared by dissolving sodium benzoate at 0.1% w/v and disodium edetate at 0.05% w/v in purified water heated to 45±2 °C in a 500 L jacketed vessel with a three-blade propeller agitator run at 300 rpm; after cooling to 25 °C, nikethamide is added slowly under continued mixing to avoid localized high-API zones. The solution is filtered through a 5 µm polypropylene bag filter and filled into 500 mL high-density polyethylene bottles with tamper-evident caps or 1 L graduated drench containers; each container is checked for deliverable volume against Ph. Eur. 2.9.18 and for preservative efficacy against Ph. Eur. 5.1.3. Microbiological quality for non-sterile aqueous oral preparations must meet Ph. Eur. 5.1.4 limits for total aerobic microbial count below 10² CFU/g. Regulatory status in food-producing ruminants is restricted: nikethamide is not included in Table 1 of Commission Regulation (EU) No 37/2010 as a substance with a maximum residue limit for food-producing species, so oral drench products are not legally acceptable for calves or lambs intended for human consumption within the EU unless an alternative national residue-control pathway is expressly permitted. Published data for extended shelf-life beyond 24 months in polyethylene containers at 30 °C/65% RH is limited. Finished product types include 500 mL dispensing bottles, 1 L drench bottles, and 100 mL hospital-use graduated oral adapters.

What Limits Content Uniformity in Direct Compression of Liquid Nikethamide Adsorbates?

The liquid state of nikethamide at 25 °C requires presorption onto a free-flowing carrier before tablet compression. A typical core formulation contains nikethamide equivalent to 100 mg per tablet, with the liquid API preadsorbed onto microcrystalline cellulose and colloidal silicon dioxide at a drug load of 50–70% w/w in the adsorbate; the adsorbate represents 35–40% w/w of the final core mass. Direct compression is performed on a rotary tablet press with 10 mm standard concave tooling, compression force maintained at 8–12 kN, and tablet hardness controlled at 50–70 N; in-process weight variation is measured every 15 minutes using a 0.1 mg readability analytical balance. If residual moisture in the adsorbate exceeds 2.0%, flow through the feed frame becomes inconsistent and weight variation drifts outside the acceptance value specified in Ph. Eur. 2.9.5, with visible sticking on lower punches at press speeds above 60 rpm. Disintegration is determined according to Ph. Eur. 2.9.7 in 900 mL water at 37±1 °C; dissolution is assessed using Ph. Eur. 2.9.3 paddle apparatus at 50 rpm in 900 mL hydrochloric acid solution 0.1 M. Because nikethamide is hygroscopic when exposed above 60% RH, precompression storage of granules above 25 °C/60% RH leads to picking and frictional heating; dehumidified rooms operating below 40% RH are required for direct compression. Film coating with hypromellose 6 cPs is applied until a 2–3% weight gain is achieved, using a perforated pan coater with inlet air at 60–65 °C. Terminal finished product types include 50 mg, 100 mg, and 150 mg veterinary film-coated tablets. Tablets are intended for canine and feline respiratory support in veterinary hospital or compounding pharmacy settings, not for food-producing animals.

For capsule-based compounding of liquid nikethamide, a pregranulated adsorbate containing 25% w/w API on colloidal silicon dioxide is filled into hard gelatin or hypromellose capsule shells on an intermittent-motion capsule filling machine operating at 60–80% of maximum speed for size 3 shells. Fill weight is controlled at 320±10 mg per capsule, equivalent to 80 mg nikethamide per capsule; content uniformity is verified against Ph. Eur. 2.9.5, and disintegration must meet Ph. Eur. 2.9.7 using water at 37±1 °C with a limit of 15 minutes. Terminal product types are 80 mg capsules in unit-dose blister packs or high-density polyethylene bottles; because capsule shell brittleness increases when storage humidity falls below 35% RH, packaging includes desiccant in aluminum-sealed containers. This route is used mainly for companion animal outpatient prescriptions and equine oral administration in non-food animals.

Granulated Oral Powders and Point-of-Administration Sachets

Granulation is required for nikethamide oral powders because direct blending of the liquid API with sucrose or dextrose produces compacted lumps within 48 hours at 25 °C/60% RH. Non-aqueous wet granulation is performed in a top-spray fluid-bed granulator using isopropanol as the granulation solvent and povidone K30 as binder at 5% w/w of dry granule mass; the liquid API is dissolved in the granulation solution at a level equivalent to 10–20% w/w of the final granule mass. Process parameters include inlet air temperature 60±5 °C, product temperature 35–40 °C, spray rate 15 g/min, and fluidizing air velocity 1.5 m/s; granulation is terminated when loss on drying falls below 2.0%, measured by Ph. Eur. 2.2.32. The dried granules are sized through a 1.0 mm oscillating sieve and filled into 2 g unit-dose sachets using a volumetric auger filler; fill-weight uniformity is verified against Ph. Eur. 2.9.5. Particle-size distribution is controlled to a D50 of 150–400 µm by laser diffraction; fines below 75 µm above 15% w/w increase dusting and segregate in the hopper, causing API content drift across sachet batches. Microbiological quality must meet Ph. Eur. 5.1.4 for oral powders, and stability testing of the sachet in polyester/aluminum/polyethylene laminate is conducted according to VICH GL3. Because the liquid API can migrate into the laminate sealant if temperature exceeds 40 °C, sachets are stored below 30 °C. Terminal finished product types include 2 g sachets delivering 100 mg nikethamide and 10 g granules for reconstitution in companion animal hospital oral syringes; the powder form is not appropriate for dry feed premix applications in food-producing animals. For direct premix use in species intended for human consumption, published data for regulatory acceptance is limited and the absence of a maximum residue limit under EU regulations prevents application without an explicit national permit.